2014
Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics
Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics. Annual Review Of Medicine 2014, 66: 1-15. PMID: 25341010, PMCID: PMC4428310, DOI: 10.1146/annurev-med-053013-062946.Peer-Reviewed Original ResearchConceptsRapid antidepressant effectsAntidepressant effectsGlutamate-based antidepressantsTolerability of ketamineRapid-acting antidepressantsTreatment-resistant depressionNeurobiology of depressionPotent antidepressant effectsRapid acting antidepressantsBiology of depressionPotential treatment targetHours of treatmentTreatment targetsKetamineAntidepressantsBiomarker studiesDepressionNeurobiologyTolerability
2010
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal JH, Mathew SJ, D’Souza D, Garakani A, Gunduz-Bruce H, Charney DS. Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. CNS Drugs 2010, 24: 669-693. PMID: 20658799, DOI: 10.2165/11533230-000000000-00000.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPreliminary clinical trialsPositive allosteric modulatorsPsychiatric disordersClinical trialsAnimal modelsAllosteric modulatorsGroup II mGluR agonistGroup IMetabotropic glutamate receptor agonistAnxiety disordersPotential psychiatric applicationsGlutamate receptor agonistsMetabotropic glutamate receptorsTreatment of schizophreniaRole of glutamateForm of depressionMGluR agonistAntidepressant propertiesMGluR5 agonistReceptor agonistGlutamate receptorsMood disordersArea of schizophreniaPromising agentAgonists
2009
Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia
Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discovery Today 2009, 14: 690-697. PMID: 19460458, PMCID: PMC2898127, DOI: 10.1016/j.drudis.2009.05.002.Peer-Reviewed Original ResearchConceptsPsychiatric disordersSymptomatic reliefMood disordersAnxiety disordersNeuroplasticity deficitsCurrent pharmacotherapyUnderlying abnormalityCurrent treatmentPsychiatric treatmentNeuroplasticityDisordersPharmacotherapyTreatmentExciting new findingsSchizophreniaReliefAbnormalitiesNeurodevelopmentNew findingsPrevention
2008
Riluzole in the Treatment of Mood and Anxiety Disorders
Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G. Riluzole in the Treatment of Mood and Anxiety Disorders. CNS Drugs 2008, 22: 761-786. PMID: 18698875, DOI: 10.2165/00023210-200822090-00004.Peer-Reviewed Original ResearchConceptsTreatment of moodAnxiety disordersMultiple molecular actionsOpen-label trialPlacebo-controlled trialAmino acid neurotransmissionCommon adverse effectsLiver function testsAmyotrophic lateral sclerosisVoltage-gated sodium channelsBorderline personality disorderSelf-injurious behaviorStandard therapyIll patientsBipolar depressionFunction testsObsessive-compulsive disorderCase reportGlutamatergic neurotransmissionGlutamate levelsExtracellular glutamateClinical consequencesLateral sclerosisAstrocytic uptakeRiluzoleTargeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 2008, 7: 426-437. PMID: 18425072, PMCID: PMC2715836, DOI: 10.1038/nrd2462.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsExcitatory Amino Acid AntagonistsGlutamatesHumansMood DisordersPsychotropic DrugsConceptsGlutamatergic systemMood disordersAntidepressant effectsNMDA antagonistsDouble-blind placebo-controlled crossover studyTreatment-resistant major depressive disorderPlacebo-controlled crossover studyGlutamate release inhibitorSignificant antidepressant effectNMDA receptor expressionRecurrent mental illnessSingle intravenous doseMajor depressive disorderPotential novel therapeuticsGlutamatergic abnormalitiesCrossover studyGlutamate releaseIntravenous doseMood stabilizersDepressive disorderReceptor expressionReceptor modulatorsEvidence of alterationsCerebrospinal fluidAMPA potentiators
2007
Naltrexone Is Associated With Reduced Drinking by Alcohol Dependent Patients Receiving Antidepressants for Mood and Anxiety Symptoms: Results From VA Cooperative Study No. 425, “Naltrexone in the Treatment of Alcoholism”
Krystal JH, Gueorguieva R, Cramer J, Collins J, Rosenheck R, Team T. Naltrexone Is Associated With Reduced Drinking by Alcohol Dependent Patients Receiving Antidepressants for Mood and Anxiety Symptoms: Results From VA Cooperative Study No. 425, “Naltrexone in the Treatment of Alcoholism”. Alcohol Clinical And Experimental Research 2007, 32: 85-91. PMID: 18070245, DOI: 10.1111/j.1530-0277.2007.00555.x.Peer-Reviewed Original ResearchConceptsEfficacy of naltrexoneGroup of patientsAlcohol-dependent patientsAntidepressant medicationDependent patientsMood symptomsDrinking daysPrescription of antidepressantsAnxiety symptomsVA Medical CenterPercent drinking daysSevere mood symptomsTreatment of alcoholismStep Facilitation TherapyDrinking-related outcomesNaltrexone prescriptionStudy medicationSignificant mood symptomsStudy patientsAntidepressant treatmentStudy entryComorbid conditionsComorbid moodMedical CenterNaltrexoneLuteal-Phase Accentuation of Acoustic Startle Response in Women with Premenstrual Dysphoric Disorder
Epperson CN, Pittman B, Czarkowski KA, Stiklus S, Krystal JH, Grillon C. Luteal-Phase Accentuation of Acoustic Startle Response in Women with Premenstrual Dysphoric Disorder. Neuropsychopharmacology 2007, 32: 2190-2198. PMID: 17314917, PMCID: PMC2713599, DOI: 10.1038/sj.npp.1301351.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderMenstrual cycle phaseMenstrual cycleHealthy womenFollicular phaseDysphoric disorderLuteal phasePhysiologic responsesMenstrual cycle-related fluctuationsStartle magnitudeCentral nervous system responseHealthy menstruating womenAcoustic startle responseAcoustic startle paradigmNervous system responsesPowerful modulatory effectsStartle response magnitudeVisual affective stimuliNeuroactive steroidsMenstruating womenASR magnitudeModulatory effectsCycle phaseNeuroendocrine milieuAcoustic startle response magnitudesAntiglutamatergic Strategies for Ethanol Detoxification: Comparison With Placebo and Diazepam
Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY, Grinenko AA, Pittman B, Gueorguieva R, Petrakis IL, Zvartau EE, Krystal JH. Antiglutamatergic Strategies for Ethanol Detoxification: Comparison With Placebo and Diazepam. Alcohol Clinical And Experimental Research 2007, 31: 604-611. PMID: 17374039, DOI: 10.1111/j.1530-0277.2007.00344.x.Peer-Reviewed Original ResearchConceptsAlcohol withdrawal symptomsWithdrawal symptomsActive medicationAlcohol withdrawalGlutamatergic activationEthanol detoxificationAspartate glutamate receptor antagonistGlutamate release inhibitorGlutamate receptor antagonistsMale alcohol-dependent inpatientsAdditional diazepamDiazepam administrationClinical evidenceStandard pharmacotherapyReceptor antagonistAlcohol-dependent inpatientsRelease inhibitorEthanol dependenceAlcohol abstinenceGlutamate receptorsReceptor inhibitorsWithdrawal severityPlaceboMedicationsNew treatmentsPediatric psychopharmacology: mood, anxiety and disruptive behavior/pervasive developmental disorders
McDougle CJ, Krystal JH. Pediatric psychopharmacology: mood, anxiety and disruptive behavior/pervasive developmental disorders. Psychopharmacology 2007, 191: 1-3. PMID: 17476481, DOI: 10.1007/s00213-007-0720-4.Peer-Reviewed Original Research
2005
GABA and glutamate systems as therapeutic targets in depression and mood disorders
Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opinion On Therapeutic Targets 2005, 9: 153-168. PMID: 15757488, DOI: 10.1517/14728222.9.1.153.Peer-Reviewed Original ResearchEffects of smoking and smoking abstinence on cognition in adolescent tobacco smokers
Jacobsen LK, Krystal JH, Mencl WE, Westerveld M, Frost SJ, Pugh KR. Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers. Biological Psychiatry 2005, 57: 56-66. PMID: 15607301, DOI: 10.1016/j.biopsych.2004.10.022.Peer-Reviewed Original ResearchConceptsAdolescent smokersVerbal memoryTobacco cravingAdolescent daily smokersNicotine withdrawalAdolescent tobacco smokersDaily tobacco smokersDivided attentionVerbal learningCognitive enhancementMemory performanceSustained attentionCognitive performanceGeneral intelligenceAdolescent nonsmokersPerformance decrementsParental educational attainmentFemale smokersDepressed moodMemoryAffective symptomsDaily smokersRecency of smokingTobacco smokersEarly age
2003
Clinical Studies Implementing Glutamate Neurotransmission in Mood Disorders
SANACORA G, ROTHMAN DL, MASON G, KRYSTAL JH. Clinical Studies Implementing Glutamate Neurotransmission in Mood Disorders. Annals Of The New York Academy Of Sciences 2003, 1003: 292-308. PMID: 14684453, DOI: 10.1196/annals.1300.018.Peer-Reviewed Original Research
2002
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments
Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Molecular Psychiatry 2002, 7: s71-s80. PMID: 11986998, DOI: 10.1038/sj.mp.4001021.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsGamma-Aminobutyric AcidGlutamic AcidHumansModels, NeurologicalMood DisordersSynaptic TransmissionConceptsCortical GABA levelsMood-stabilizing treatmentMood disordersGABA levelsΓ-amino-butyric acid (GABA) systemMood-stabilizing agentsGlutamate receptor functionDevelopment of medicationsGABA deficitAvailable antidepressantsGABAergic modulationAntimanic effectsGlutamatergic activityClinical evidenceNovel antidepressantsGABA systemAntidepressant drugsNew agentsReceptor functionAvailable evidenceReceptor targetsAntidepressantsDisordersGlutamateTreatment
1986
Assessment of alexithymia in posttraumatic stress disorder and somatic illness: introduction of a reliable measure.
Krystal JH, Giller EL, Cicchetti DV. Assessment of alexithymia in posttraumatic stress disorder and somatic illness: introduction of a reliable measure. Psychosomatic Medicine 1986, 48: 84-94. PMID: 3945719, DOI: 10.1097/00006842-198601000-00007.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderBeth Israel Psychosomatic QuestionnaireSomatic illnessStress disorderOutpatient treatmentAffective patientsAffective disordersPsychiatric inpatientsPatientsSchalling-Sifneos ScaleComparison groupAssessment of alexithymiaMedical servicesInterrater reliabilityPsychosomatic researchVietnam veteransDisordersSimilar degreeInpatientsGreater degreePsychosomatic QuestionnaireIllnessMMPI subscalesSomatic groupsReliable measure